WE HAVE A RICH PIPELINE OF INNOVATIVE NEW MOLECULAR ENTITIES

**ONCOLOGY**

- **PHASE 1**
  - **TAK-252**
    - Target: BRAF
    - Indications: Melanoma, colorectal cancer
  - **TAK-573**
    - Target: FGFR2
    - Indications: Solid tumors
  - **TAK-079**
    - Target: Anti-CDS1
    - Indications: R/R MM
  - **TAK-164**
    - Target: Anti-HER2
    - Indications: Breast cancer

- **PHASE 2**
  - **TAK-228**
    - Target: Anti-EGF
    - Indications: R/R MM
  - **TAK-788**
    - Target: EGFR inhibitor
    - Indications: NSCLC
  - **TAK-931**
    - Target: CD277 inhibitor
    - Indications: AML/MLL
  - **TAK-851**
    - Target: Anti-MUC1
    - Indications: GI malignancies

- **PHASE 3/FILED**
  - **TAK-659**
    - Target: Anti-HER2
    - Indications: Endometrial cancer
  - **TAK-385**
    - Target: Anti-HER2
    - Indications: Prostate cancer
  - **TAK-924**
    - Target: Anti-PDL1
    - Indications: HR-MDS/CMM.

**GASTRO-ENTEROLOGY**

- **RARE DISEASES**
  - **TAK-951**
    - Target: Peptide agonist
    - Indications: Nausea & vomiting
  - **Kuma062**
    - Target: PDE5 inhibitor
    - Indications: Erectile dysfunction
  - **TAK-018**
    - Target: FGFR2
    - Indications: Gastrointestinal stromal tumor
  - **TAK-905**
    - Target: FGFR2
    - Indications: Gastrointestinal stromal tumor

**NEUROSCIENCE**

- **PHASE 1**
  - **TAK-531**
    - Target: Anti-shRNA
    - Indications: Hunter CNS (IT)
  - **TAK-754**
    - Target: Anti-shRNA
    - Indications: Gaucher disease
  - **TAK-607**
    - Target: Anti-shRNA
    - Indications: Chronic lymphocytic leukemia
  - **TAK-611**
    - Target: Anti-shRNA
    - Indications: MLD

- **PHASE 2**
  - **TAK-609**
    - Target: Anti-shRNA
    - Indications: Hunter disease
  - **TAK-755**
    - Target: Anti-shRNA
    - Indications: Hunter disease

**PLASMA-DERIVED THERAPIES**

- **TOK-021**
  - Target: EVT Vaccine
  - Indications: Dengue vaccine

**VACCINES**

- **TOK-426**
  - Target: Zika Vaccine

- **TOK-214**
  - Target: Norovirus Vaccine

**APPROVED**

- **NINLARO**
  - Target: Proteosome inhibitor
  - Indications: Multiple myeloma
- **ADCETRIS**
  - Target: CD30 ADC
  - Indications: Hodgkin lymphoma
- **ICLUSIG**
  - Target: BCR-ABL inhibitor
- **ALUNBRIG**
  - Target: ALK inhibitor
  - Indications: ALK+ NSCLC
- **ENTYvio**
  - Target: Anti-IL22 antibody
  - Indications: Psoriasis
- **ELOCTATE**
  - Target: Alpha-1 antitrypsin inhibitor
  - Indications: AAT deficiency
- **BILOQ**
  - Target: Anti-IL6R antibody
  - Indications: GvHD
- **ALSOFEL**
  - Target: Mesenchymal stem cells
  - Indications: ALS
- **GYK**
  - Target: Anti-IL22 antibody
  - Indications: Psoriasis
- **STENTYS**
  - Target: Anti-IL22 antibody
  - Indications: Psoriasis
- **REAVEN**
  - Target: Anti-IL22 antibody
  - Indications: Psoriasis
- **RMMK**
  - Target: Anti-IL22 antibody
  - Indications: Psoriasis
- **RTX**
  - Target: Anti-CD20 antibody
  - Indications: Non-Hodgkin lymphoma

---

*With ongoing significant clinical development activities; Pipeline as of July 31, 2019

Pipeline not all inclusive; programs also ongoing in other Therapeutic Areas. For glossary of disease abbreviations please refer to appendix.

---

- Stage-ups since earnings announcement May 14, 2019
- Stage-ups/additions since April 1, 2019
- Orphan Drug Designation
- (in any region / indication for a given asset)
- Potential for registration enabling Ph-2 study
- Assets shown in Phases 1-3 explicitly refer to new molecular entities
## MAXIMIZING THE VALUE OF OUR APPROVED PROGRAMS

### PHASE 1

<table>
<thead>
<tr>
<th>ONCOLOGY</th>
<th>GASTRO-ENTEROLOGY</th>
<th>RARE DISEASES</th>
<th>NEUROSCIENCE</th>
<th>PLASMA-DERIVED THERAPIES</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALUNBRIG® ALK inhibitor 1L ALK+NSCLC (CN)</td>
<td>ALUNBRIG® ALK inhibitor 2L ALK+NSCLC (JP, EU)</td>
<td>NATPARA</td>
<td>BUCCOLAM GABA-Agosteric Modulator Status Epilepticus (JP)</td>
<td>CINRYZE PID C1 Inhibitor HAE prophylaxis (JP)</td>
</tr>
<tr>
<td>Cabozantinib ALK inhibitor 2L RCC (JP)</td>
<td>ICLUSIG® BCR-ABL inhibitor TKI rec, clinical phase CN, EU</td>
<td>VONVENDE VONVENDE vWD replacement VONVENDE pediatric</td>
<td>VONVENDE VONVENDE vWF replacement VONVENDE pediatric</td>
<td></td>
</tr>
<tr>
<td>Niraparib PARP 1/2 inhibitor 1L ovarian cancer — maintenance (JP)</td>
<td>NINLARO® Proteasome inhibitor R/R MM triplets (US)</td>
<td>OBIZUR</td>
<td>HYQVIA HYQVIA HAE prophylaxis (JP)</td>
<td>TRINTELIX™ TRINTELIX™ Nebinib IBD (JP)</td>
</tr>
<tr>
<td></td>
<td>NINLARO® Proteasome inhibitor R/R MM triplets (JP)</td>
<td>ADYNOVATE Pediatric Hema (EU)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALUNBRIG® ALK inhibitor 2L ALK+NSCLC 2nd gen TKI (GL)</td>
<td>ENTYVIO® α4β7 mAb SubQ UC (US)</td>
<td>ADRETIS® Seattle Genetics CHIR 99021 1L ALK+NSCLC (CN)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### PHASE 2

<p>| | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### PHASE 3

<p>| | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### FILED

<p>| | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Pipeline as of July 31, 2019; region abbreviations: GL = global (USA, Europe, Japan, China). Pipeline not all inclusive; programs also ongoing in other Therapeutic Areas

For glossary of disease abbreviations please refer to appendix